Mesothelioma carries one of the more difficult prognoses among cancers, with a median overall survival of about 15 months across all types and stages. But that single number obscures a wide range of outcomes. Some patients live only a few months, while others survive five years or longer depending on where the cancer develops, what cell type it is, how early it’s caught, and which treatments are available.
How Location Affects Survival
Mesothelioma develops in the thin tissue lining certain organs, most commonly the lungs (pleural mesothelioma) and less often the abdomen (peritoneal mesothelioma). Rare cases arise in the lining around the heart or the testicles.
At first glance, population-level data shows peritoneal mesothelioma faring worse than pleural, with a median survival of 4.7 months versus 8.7 months when looking at all patients regardless of treatment. With chemotherapy, those numbers improve to about 8.9 months for peritoneal and 12.7 months for pleural. However, peritoneal patients who qualify for a specialized surgical approach that combines tumor removal with heated chemotherapy delivered directly into the abdomen see dramatically better results: a median survival of 53 months, with about 47% alive at five years. That gap highlights how much treatment access shapes the picture.
Pericardial mesothelioma, which forms around the heart, is extremely rare and generally carries the poorest outlook, though reliable survival statistics are limited because so few cases are diagnosed.
Survival by Stage at Diagnosis
Stage matters, though perhaps less dramatically than with some other cancers. Data from England covering patients diagnosed between 2013 and 2017 shows the following one-year survival rates:
- Stage 1: About 60% survive one year or more
- Stage 2: About 55% survive one year or more
- Stage 3: About 50% survive one year or more
- Stage 4: About 30% survive one year or more
The difference between stages 1 and 3 is smaller than you might expect, partly because mesothelioma grows along surfaces rather than forming a single mass, making it difficult to fully remove even when caught early. The real drop-off comes at stage 4, when the cancer has spread to distant organs.
One complicating factor: most patients are diagnosed in advanced stages. The early symptoms, typically shortness of breath and chest pain, overlap with many common conditions, so the path to a mesothelioma diagnosis is often long. Whether catching it earlier would consistently improve survival remains an open question, since even localized disease is hard to treat completely.
Cell Type Is a Major Factor
Under a microscope, mesothelioma cells fall into three categories: epithelioid, sarcomatoid, and biphasic (a mix of both). Epithelioid is the most common and responds best to treatment. Sarcomatoid is the most aggressive and hardest to control. Biphasic falls somewhere in between, depending on how much of each cell type is present.
The impact of cell type shows up clearly in immunotherapy data. In a major clinical trial called CheckMate 743, patients with non-epithelioid (mostly sarcomatoid) mesothelioma treated with immunotherapy had a five-year survival rate of 12%, compared to just 1% with chemotherapy alone. For epithelioid cases, the gap was narrower: 14% versus 8%. In other words, cell type not only affects baseline prognosis but also determines how well certain treatments work.
Age and Gender
Younger patients generally do better, in part because they’re more likely to tolerate aggressive treatments like surgery. About 88% of mesothelioma patients are male, reflecting decades of occupational asbestos exposure in industries like construction, shipbuilding, and manufacturing. Women diagnosed with mesothelioma tend to be younger and are more likely to have the epithelioid cell type, both of which improve their starting position.
Even after adjusting for age, cell type, and fitness level, women still show a roughly 15% lower risk of death compared to men. Researchers believe estrogen may play a protective role, though the exact mechanism isn’t fully understood.
How Treatment Changes the Outlook
The combination of treatments a patient receives is one of the strongest predictors of how long they’ll live. A study comparing different treatment approaches in pleural mesothelioma found clear survival differences:
- Chemotherapy alone: median survival of 11.7 months
- Immunotherapy plus chemotherapy: 18.2 months
- Surgery plus chemotherapy: 20.7 months
- Surgery, immunotherapy, and chemotherapy combined: 22.6 months
These numbers show that adding treatments in combination can roughly double survival compared to chemotherapy alone. Not everyone is a candidate for multimodal therapy, though. Eligibility depends on the cancer’s stage, location, cell type, and the patient’s overall health and fitness.
Surgery Options
Two main surgical approaches exist for pleural mesothelioma. One removes the lung entirely along with the surrounding lining. The other preserves the lung and strips away just the diseased tissue. A meta-analysis of over 2,900 patients found no significant difference in two-year survival between the two approaches, but the lung-removing procedure carried about 2.5 times the risk of dying within 30 days of surgery (4.5% versus 1.7%). Because of this, the lung-sparing approach has become more common.
Immunotherapy’s Growing Role
Immunotherapy has changed the treatment landscape, particularly for patients with aggressive cell types. The CheckMate 743 trial, which followed patients for over five years, found that combining two immunotherapy drugs as a first-line treatment produced a five-year survival rate of 14%, compared to 6% with standard chemotherapy. The benefit was especially striking for non-epithelioid cases, where five-year survival went from 1% with chemotherapy to 12% with immunotherapy. This represented the first major improvement in first-line treatment for mesothelioma in nearly two decades.
What Shapes an Individual Prognosis
Population statistics describe averages, but individual outcomes depend on a cluster of factors working together. The variables that most strongly influence survival include the cancer’s location and stage, cell type, your age and physical fitness at diagnosis, and which treatments you’re able to receive. A 55-year-old woman with early-stage epithelioid pleural mesothelioma who can undergo surgery and immunotherapy faces a very different outlook than a 75-year-old man with stage 4 sarcomatoid disease.
Performance status, a measure of how well you can carry out daily activities, is one of the most reliable predictors. Patients who are relatively active and independent at the time of diagnosis consistently do better, partly because they can tolerate more aggressive treatment and partly because it reflects a less advanced disease burden.
While mesothelioma remains a serious diagnosis, the gap between the worst and best outcomes is wider than the median survival number suggests. Treatment advances, particularly in immunotherapy, have expanded the group of patients who reach the three- and five-year marks, a shift that was uncommon even a decade ago.